Personal information

Activities

Employment (1)

Baylor College of Medicine : Houston, TX, US

Professor (Medicine, Molecular and Cellular Biology)
Employment
Source: Self-asserted source
Rachel Schiff

Funding (14)

MECHANISMS OF RESISTANCE TO HER2 AND ER-TARGETED THERAPIES AND NOVEL THERAPEUTIC STRATEGIES

2023-10-01 to 2024-09-30 | Grant
The Breast Cancer Research Foundation Inc. (New York, US)
GRANT_NUMBER:

BCRF-23-145

Source: check_circle
BCRF ProposalCentral

Mechanisms of Resistance to HER2 and ER-targeted Therapies and Novel Therapeutic Strategies

2022-10-01 to 2023-09-30 | Grant
The Breast Cancer Research Foundation Inc. (New York, US)
GRANT_NUMBER:

BCRF-22-145

Source: check_circle
BCRF ProposalCentral

Mechanisms of Resistance to HER2 and ER-targeted Therapies and Novel Therapeutic Strategies

2021-10-01 to 2022-09-30 | Grant
The Breast Cancer Research Foundation Inc. (New York, US)
GRANT_NUMBER:

BCRF-21-145

Source: check_circle
BCRF ProposalCentral

Mechanisms of Resistance to HER2 and ER-targeted Therapies and Novel Therapeutic Strategies

2020-10-01 to 2021-09-30 | Grant
The Breast Cancer Research Foundation Inc. (New York, US)
GRANT_NUMBER:

2020-Schiff-1944

Source: check_circle
BCRF ProposalCentral

Mechanisms of Resistance to HER2 and ER-targeted Therapies and Novel Therapeutic Strategies

2019-10-01 to 2020-09-30 | Grant
The Breast Cancer Research Foundation Inc. (New York, US)
GRANT_NUMBER:

2019-Schiff-1778

Source: check_circle
BCRF ProposalCentral

Mechanisms of Resistance to HER2 and ER-targeted Therapies and Novel Therapeutic Strategies

2018-10-01 to 2019-09-30 | Grant
The Breast Cancer Research Foundation Inc. (New York, US)
GRANT_NUMBER:

2018-Schiff-1572

Source: check_circle
BCRF ProposalCentral

Mechanisms of Resistance to HER2 and ER-targeted Therapies and Novel Therapeutic Strategies

2017-10-01 to 2018-09-30 | Grant
The Breast Cancer Research Foundation Inc. (New York, US)
GRANT_NUMBER:

2017-Schiff-1293

Source: check_circle
BCRF ProposalCentral

Mechanisms of Resistance to HER2 and ER-targeted Therapies and Novel Therapeutic Strategies

2016-10-01 to 2017-09-30 | Grant
The Breast Cancer Research Foundation Inc. (New York, US)
GRANT_NUMBER:

2016-Schiff-1029

Source: check_circle
BCRF ProposalCentral

Mechanisms of Resistance to HER2 and ER-targeted Therapies and Novel Therapeutic Strategies

2015-10-01 to 2016-09-30 | Grant
The Breast Cancer Research Foundation Inc. (New York, US)
GRANT_NUMBER:

2015-Schiff-796

Source: check_circle
BCRF ProposalCentral

Mechanisms of Resistance to HER2 and ER-targeted Therapies and Novel Therapeutic Strategies

2014-10-01 to 2015-09-30 | Grant
The Breast Cancer Research Foundation Inc. (New York, US)
GRANT_NUMBER:

2014-Schiff-2545

Source: check_circle
BCRF ProposalCentral

Mechanisms of Resistance to HER2 and ER-targeted Therapies and Novel Therapeutic Strategies

2013-07-26 to 2018-02-22 | Grant
The Breast Cancer Research Foundation Inc. (New York, US)
GRANT_NUMBER:

2013-Schiff-450

Source: check_circle
BCRF ProposalCentral

Identifying and Co-targeting Signaling Nodes to Circumvent Therapy Resistance in HER2+ and ER+ Breast Cancer

2012-07-24 to 2018-02-22 | Grant
The Breast Cancer Research Foundation Inc. (New York, US)
GRANT_NUMBER:

2012-Schiff-300

Source: check_circle
BCRF ProposalCentral

Identifying and Co-targeting Signaling Nodes to Circumvent Therapy Resistance in HER2+ and ER+ Breast Cancer

2011-07-29 to 2018-02-22 | Grant
The Breast Cancer Research Foundation Inc. (New York, US)
GRANT_NUMBER:

2011-Schiff-268

Source: check_circle
BCRF ProposalCentral

Identifying and co-targeting signaling nodes to circumvent therapy resistance in HER2+ and ER+ breast cancer

2010-07-29 to 2018-02-22 | Grant
The Breast Cancer Research Foundation Inc. (New York, US)
GRANT_NUMBER:

2010-Schiff-6

Source: check_circle
BCRF ProposalCentral

Works (8)

Abstract MS1-1: Oncogene signal transduction and antiestrogen resistance

Cancer Research
2023 | Journal article
Contributors: Schiff, Rachel
Source: Self-asserted source
Rachel Schiff

Abstract P1-13-17: Hyperactivation of the EGFR pathway is associated with resistance to tucatinib in HER2-positive breast cancer models

Cancer Research
2023 | Journal article | Investigation
Contributors: Liao, Fu-Tien; Gordon, Tia; Liu, Chia Chia; Selenica, Pier; Zhu, Yingjie; Patel, Juber; Nanda, Sarmistha; Qin, Lanfang; Fu, Xiaoyong; Gazzo, Andrea et al.
Source: Self-asserted source
Rachel Schiff

Abstract P2-03-10: DNA replication licensing is associated with resistance to CDK4/6 inhibitors in ER-positive breast cancer

Cancer Research
2023 | Journal article
Contributors: Nanda, Sarmistha; Shea, Martin J; Schiff, Rachel; Osborne, C Kent; Rimawi, Mothaffar; Fu, Xiaoyong
Source: Self-asserted source
Rachel Schiff

Metastatic models of resistance to next generation tyrosine kinase inhibitors (TKIs) in HER2-positive breast cancer (BC)

Cancer Research
2023-04-04 | Conference abstract
Part of ISSN: 1538-7445
Contributors: Qin, Lanfang; Shea, Martin J; Bado, Igor; Wu, Yi-Hsuan; Wu, Ling; Gao, Yang; Nanda, Sarmistha; Gordon, Tia; Liu, Chia Chia; others et al.
Source: Self-asserted source
Rachel Schiff

Abstract PD10-03: PD10-03 Super-enhancer-oriented integrative bioinformatics identifies aberrant KLF4 signaling in endocrine-resistant breast cancer (BC)

Cancer Research
2023-03-01 | Journal article
Contributors: Liu, Chia Chia; Qin, Lanfang; Sathe, Shanunak; Nanda, Sarmistha; Veeraraghavan, Jamunarani; Cohen, Ofir; Wagle, Nikhil; Rimawi, Mothaffar; Osborne, C Kent; Fu, Xiaoyong et al.
Source: Self-asserted source
Rachel Schiff

Effect of mevalonate pathway inhibitors on outcomes of patients (pts) with HER2-positive early breast cancer (BC) in the ALTTO trial.

2022 | Other
Contributors: De Angelis, Carmine; Veeraraghavan, Jamunarani; Sethunath, Vidyalakshmi; Ameye, Lieveke; Paesmans, Marianne; El-Abed, Sarra; Choudhury, Anup; Napoleone, Sylvia; Chumsri, Saranya; Piccart-Gebhart, Martine J et al.
Source: Self-asserted source
Rachel Schiff

Elacestrant and the Promise of Oral SERDs

Journal of Clinical Oncology
2022 | Other
Contributors: Sanchez, Katherine G; Nangia, Julie R; Schiff, Rachel; Rimawi, Mothaffar F
Source: Self-asserted source
Rachel Schiff

Towards personalized treatment for early stage HER2-positive breast cancer

Nature Reviews Clinical Oncology
2020-04-13 | Journal article
Contributors: Kristina Goutsouliak; Jamunarani Veeraraghavan; Vidyalakshmi Sethunath; Carmine De Angelis; C. Kent Osborne; Mothaffar F. Rimawi; Rachel Schiff
Source: check_circle
Crossref

Peer review (6 reviews for 4 publications/grants)

Review activity for Drug resistance updates. (1)
Review activity for Nature cancer. (1)
Review activity for Nature reviews. (1)
Review activity for NPJ breast cancer. (3)